An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece

GlaxoSmithKline0 sites1,100 target enrollmentMarch 2004

ConditionsType 2 Diabetes Mellitus CV Risk

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type 2 Diabetes Mellitus
Sponsor: GlaxoSmithKline
Enrollment: 1100
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.

Registry

clinicaltrials.gov

Start Date

March 2004

End Date

TBD

Last Updated

17 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Patients with ALT \> 2.5x the normal value
•With heart failure symptoms
•With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates
•With recent myocardial infarction (\<6 months)
•With severe renal disfunction
•Pregnant or lactating or planned to be pregnant during the study
•Under investigational drug treatment
•Alcoholic or drug abuser